MedAssets multiple poised to expand several times, says Sterne Agee Sterne Agee expects MedAssets to benefit from mounting margin pressure on hospitals, and the firm thinks the stock is "drastically undervalued" compared with its peers. It keeps a $30 price target and Buy rating on the stock.
News For MDAS From The Last 14 Days
Check below for free stories on MDAS the last two weeks.
MedAssets upgraded to Outperform from Market Perform at Leerink Leerink upgraded MedAssets to Outperform citing the pullback in shares since the Q2 results, the potential for improving volumes in Q3 and the company's total portfolio approach. The firm has a $26 price target for shares.